Data from First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies

Autor: Razelle Kurzrock, Shannon R. Morris, Thomas A. Lampkin, Deborah A. Smith, Laurel Adams, Michael Durante, Joseph F. Kleha, Neeraj Agarwal, Emily Bergsland, E. Claire Dees, Theresa L. Werner, Petronella O. Witteveen, Jennifer Specht, Ruud van der Noll, Jan H.M. Schellens, David Hong, Rahul Aggarwal, Pamela Munster

Purpose: GSK2126458 (GSK458) is a potent inhibitor of PI3K (α, β, γ, and δ), with preclinical studies demonstrating broad antitumor activity. We performed a first-in-human phase I study in patients with advanced solid tumors.Materials and Methods

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b58210558b93cf8d4ce8c9aff837b458
https://doi.org/10.1158/1078-0432.c.6524799

Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)

Autor: Maja J.A. de Jonge, Jan H.M. Schellens, Diane A.J. van der Biessen, Andre T. Brunetto, Agnes Jager, Johann S. de Bono, Joo Ern Ang, Martijn P. Lolkema, Jacques De Greve, Hendrik-Tobias Arkenau, Ruud van der Noll, Ilian Tchakov, Jos H. Beijnen, Marja Mergui-Roelvink, Serena Marchetti

Publikováno v: Investigational New Drugs, 38(4), 1096-1107. Kluwer Academic
Investigational New Drugs, 38. Kluwer Academic Publishers

Background In the first part of this extensive phase I study (NCT00516724), continuous olaparib twice daily (bid) with carboplatin and/or paclitaxel resulted in myelosuppression and dose modifications. Here, we report the safety, tolerability, and ef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::082dde6f0d16999d82d6405628aff352
https://doi.org/10.1007/s10637-019-00857-6

Basket of baskets (BoB): A modular, open label, phase II, multicenter study to evaluate targeted agents in molecularly selected populations with advanced solid tumors

Autor: Gerrit A. Meijer, Rodrigo Dienstmann, Alejandro Piris-Giménez, Irene Brana, Richard D. Baird, David Tamborero, Jose-Ezequiel Martin, Lodewyk F. A. Wessels, Frans L. Opdam, Ana Vivancos, Luigi De Petris, Elena Garralda, Elena Chavarria, Jordi Rodon, Claudio Vernieri, Richard F. Schlenk, Susana Muñoz, Fabien Calvo, Ruud van der Noll, Christophe Massard

Publikováno v: Journal of Clinical Oncology. 37:TPS3151-TPS3151

TPS3151 Background: Basket trials with targeted agents can show high response rates for tumors with specific molecular profiles, granting extension of the label of some drugs. In other cases, study results were disappointing, likely due to the rarity

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::597e17fe00f3789a17f0220bfaa98807
https://doi.org/10.1200/jco.2019.37.15_suppl.tps3151

Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations

Autor: Jean H. Hoffman-Censits, Juergen Wolf, Jacques Medioni, Matthew D. Galsky, Ruud van der Noll, Randi Isaacs, Sumanta K. Pal, Christian Dittrich, Katie Parker, Amir Mortazavi, Xueying Chen, Howard A. Burris, Gwenaelle Gravis, Pablo Maroto, Dean F. Bajorin, Bhumsuk Keam, Raanan Berger, David I. Quinn, Jonathan E. Rosenberg, Jae-Lyun Lee

Publikováno v: Journal of Clinical Oncology. 34:4517-4517

4517Background: FGFR3 alterations are frequent in UC (≈ 21%) and have a putative role in pathogenesis and progression. Antitumor activity observed in pts with UC in a phase 1 trial of the FGFR inhi...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b2d25673ad12bc274970e47a17195518
https://doi.org/10.1200/jco.2016.34.15_suppl.4517

Results of OAK: A phase 1, open-label, multicentre study to compare two dosage forms of AZD5363 and to explore the effect of food on the pharmacokinetic (PK) exposure, safety, and tolerability of AZD5363 in patients with advanced solid malignancies

Autor: Matthew G Krebs, Steve Evans, Emma Dean, Ruud van der Noll, James W.T. Yates, Udai Banerji, Andrew Foxley, Ed Casson, Justin P.O. Lindemann, Taylor Nigel Phillip, Paul Rugman, Begona Jimenez, Shaista Salim, Peter Lawrence, Jan H.M. Schellens, Turner Guy

Publikováno v: Journal of Clinical Oncology. 33:2577-2577

2577 Background: AZD5363 is a potent pan-Akt inhibitor and acts on cancers by blocking a cell survival pathway. AZD5363, administered to patients in the fasted state, was originally formulated as a...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9e7a37b7585e7b0d03bc7852b80362b0
https://doi.org/10.1200/jco.2015.33.15_suppl.2577